Australian Ovarian Cancer Study (AOCS): A multidisciplinary ovarian cancer resource for the genomic era
澳大利亚卵巢癌研究 (AOCS):基因组时代的多学科卵巢癌资源
基本信息
- 批准号:nhmrc : 400413
- 负责人:
- 金额:$ 93.65万
- 依托单位:
- 依托单位国家:澳大利亚
- 项目类别:NHMRC Enabling Grants
- 财政年份:2006
- 资助国家:澳大利亚
- 起止时间:2006-01-01 至 2013-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level, to identify genetic risk factors, or to understand the interaction of genes and environment. Recognizing that a large collaborative study was the only way to achieve sufficient power to address major translational questions in ovarian cancer, the Australian Ovarian Cancer Study was established and is now the largest study of its kind in the world. This proposal aims to maintain and add value to this unique resource for ovarian cancer research.
卵巢癌相对不常见,组织学上非常多样化,这使得很难在分子水平上分析卵巢癌,确定遗传风险因素,或了解基因与环境的相互作用。认识到大型合作研究是获得足够力量解决卵巢癌主要转化问题的唯一途径,澳大利亚卵巢癌研究成立了,现在是世界上同类研究中规模最大的。本提案旨在维护和增加卵巢癌研究这一独特资源的价值。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
A/Pr Dorota Gertig其他文献
A/Pr Dorota Gertig的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('A/Pr Dorota Gertig', 18)}}的其他基金
Randomised controlled trial of HPV self-sampling for improving participation in cervical screening: the iPAP trial
HPV 自我采样提高宫颈筛查参与度的随机对照试验:iPAP 试验
- 批准号:
nhmrc : 1045346 - 财政年份:2013
- 资助金额:
$ 93.65万 - 项目类别:
Project Grants
Microarray-targeted candidate gene approach to finding ovarian cancer susceptibility genes
微阵列靶向候选基因方法寻找卵巢癌易感基因
- 批准号:
nhmrc : 389867 - 财政年份:2006
- 资助金额:
$ 93.65万 - 项目类别:
NHMRC Project Grants
Exposure to high dose estrogens in adolescence: long term effects on mammographic breast density
青春期接触高剂量雌激素:对乳房 X 光检查乳腺密度的长期影响
- 批准号:
nhmrc : 403002 - 财政年份:2006
- 资助金额:
$ 93.65万 - 项目类别:
NHMRC Project Grants
Epidemiology of Hereditary Haemochromatosis
遗传性血色病的流行病学
- 批准号:
nhmrc : 251668 - 财政年份:2003
- 资助金额:
$ 93.65万 - 项目类别:
NHMRC Project Grants
Why do some breast cancers present at an advanced stage in women in Australia?
为什么澳大利亚女性的一些乳腺癌已处于晚期?
- 批准号:
nhmrc : 197801 - 财政年份:2002
- 资助金额:
$ 93.65万 - 项目类别:
NHMRC Project Grants
相似海外基金
An optical lipid sensor for the detection of ovarian cancer biomarkers in blood
用于检测血液中卵巢癌生物标志物的光学脂质传感器
- 批准号:
24K17704 - 财政年份:2024
- 资助金额:
$ 93.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Decoding the impact of single cell mutational processes in triple negative breast cancer and high grade serous ovarian cancer
解读单细胞突变过程对三阴性乳腺癌和高级别浆液性卵巢癌的影响
- 批准号:
477662 - 财政年份:2023
- 资助金额:
$ 93.65万 - 项目类别:
Operating Grants
Combination of plasma gelsolin with radiological imaging for prognostication of ovarian cancer
血浆凝溶胶蛋白与放射成像相结合用于卵巢癌的预后
- 批准号:
495885 - 财政年份:2023
- 资助金额:
$ 93.65万 - 项目类别:
Miscellaneous Programs
Exploring ATR and PARP Inhibitors for Ovarian Cancer Management: An Innovative Approach
探索 ATR 和 PARP 抑制剂用于卵巢癌治疗:一种创新方法
- 批准号:
494635 - 财政年份:2023
- 资助金额:
$ 93.65万 - 项目类别:
Operating Grants
Exploring immune checkpoint pathways as novel therapeutic targets in ovarian cancer
探索免疫检查点通路作为卵巢癌的新治疗靶点
- 批准号:
22KK0268 - 财政年份:2023
- 资助金额:
$ 93.65万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Engineering T cells to overcome inhibitory receptor signals that limit the efficacy of adoptive cell therapy against ovarian cancer
改造 T 细胞以克服抑制性受体信号,这些信号限制了过继性细胞疗法对卵巢癌的疗效
- 批准号:
10526155 - 财政年份:2023
- 资助金额:
$ 93.65万 - 项目类别:
Lipid molecules regulate the prolifetation of ovarian cancer via LSR
脂质分子通过LSR调节卵巢癌的增殖
- 批准号:
23K19506 - 财政年份:2023
- 资助金额:
$ 93.65万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Experiences of Discrimination, Dysbiosis, and Racial Disparities in Ovarian Cancer
卵巢癌中的歧视、生态失调和种族差异的经历
- 批准号:
10371537 - 财政年份:2023
- 资助金额:
$ 93.65万 - 项目类别:
Role of miR-195 in Chemo-Resistant Ovarian Cancer
miR-195 在化疗耐药性卵巢癌中的作用
- 批准号:
10640540 - 财政年份:2023
- 资助金额:
$ 93.65万 - 项目类别:
Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer
衰老相关分泌表型的信号基础及其在上皮性卵巢癌中的意义
- 批准号:
10731600 - 财政年份:2023
- 资助金额:
$ 93.65万 - 项目类别:














{{item.name}}会员




